Aligos Therapeutics ALGS 深 滬
等待開盤 09-25 09:30:00 美东时间
5.55
-0.010
-0.18%
華盛通- 最 高5.695
- 今 開5.55
- 成交量 5.96万股
- 最 低 5.27
- 昨 收 5.56
- 總市值 3465.73万
- 52周最高 13.6892
- 市盈率 靜 --
- 換手率 0.95%
- 52周最低 3.98
- 委 比 97.93%
- 總股本 624.46万
- 歷史最高 937.75
- 量 比 1.07
- 振 幅 7.64%
- 歷史最低 3.76
- 每 手 1
- 風險率 1.82%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
Shares of Lobo Technologies Ltd (NASDAQ:LOBO) rose sharply in pre-market trading after the company reported a year-over-year increase in H1 financial results. Lobo EV Technologies posted a H1 loss of 7 cents per share, versus a year-ago loss of 28 cents per share. The company’s sales rose to $14.587...
09-21 17:01
Aligos Therapeutics Amends Long-Term Headquarters Lease Agreement
Aligos Therapeutics ( ($ALGS) ) has issued an update. On September 10, 2026, Al...
09-16 04:37
Aligos Therapeutics to Present at the Cantor Global Healthcare Conference
Aligos Therapeutics, Inc. (NASDAQ: ALGS), a clinical-stage biopharmaceutical company focused on developing best-in-class therapies for liver and viral diseases, announced that its management will participate in the Cantor Global Healthcare Conference. The company's representatives will engage in a Fireside Chat on Wednesday, September 9, 2026, at 8:00 AM ET. The presentation will be available on Aligos’ website and a replay will be accessible for...
09-02 12:00
Aligos Therapeutics shares are trading higher after the company reported better-than-expected Q2 earnings results.
Aligos Therapeutics shares are trading higher after the company reported better-than-expected Q2 earnings results.
08-07 01:07
Aligos Therapeutics Q2 EPS $(0.14) Beats $(1.07) Estimate, Sales $0.000 Miss $18.243M Estimate
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(1.07) by 86.92 percent. This is a 90.85 percent increase over losses of $(1.53) per share from the same period last year. The company reported quarterly sales of $0.100 whi...
08-06 20:02
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
Aligos Therapeutics reported Q2 2026 business progress and financial results. The company strengthened its financial position with a $25M upfront payment from Amoytop for the Greater China license of pevifoscorvir sodium. Pevifoscorvir sodium achieved Breakthrough Therapy Designation in China and completed enrollment in the Phase 2 B-SUPREME study. ALG-170675, an ASO for chronic HBV, received IND approval in China. Financially, the company report...
08-06 12:00
Aligos Therapeutics Receives Upfront Payment Of $25M From Exclusive License Deal Of Pevifoscorvir Sodium In Greater China With Xiamen Amoytop; Pevifoscorvir Granted Breakthrough Therapy Designation
Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it has received the upfront payment of $25M USD from the exclusive license deal of pevifoscorvi...
07-07 04:07
Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
Aligos Therapeutics announced the receipt of a $25M upfront payment from its exclusive license deal with Amoytop for pevifoscorvir sodium in Greater China. The drug was granted Breakthrough Therapy Designation by China's NMPA, enabling priority review. Aligos is eligible for up to $420M in milestones and royalties, while retaining rights in key markets like the U.S., Europe, Japan, and South Korea. CEO Lawrence Blatt highlighted the collaboration...
07-06 20:05
美股大行评级 | 瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
05-29 18:09
Lake Street Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $45
Lake Street analyst Daniel Brims initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and announces Price Target of $45.
05-29 01:18
